- Home
- EDF vs CYBN Comparison
EDF vs CYBN Comparison
Compare EDF & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- CYBN
- Stock Information
- Founded
- EDF 2010
- CYBN 2019
- Country
- EDF United States
- CYBN Canada
- Employees
- EDF N/A
- CYBN N/A
- Industry
- EDF Investment Managers
- CYBN Pharmaceuticals and Biotechnology
- Sector
- EDF Finance
- CYBN Health Care
- Exchange
- EDF Nasdaq
- CYBN Nasdaq
- Market Cap
- EDF 160.2M
- CYBN 176.5M
- IPO Year
- EDF N/A
- CYBN N/A
- Fundamental
- Price
- EDF $5.03
- CYBN $6.22
- Analyst Decision
- EDF
- CYBN Strong Buy
- Analyst Count
- EDF 0
- CYBN 3
- Target Price
- EDF N/A
- CYBN $85.00
- AVG Volume (30 Days)
- EDF 160.6K
- CYBN 717.1K
- Earning Date
- EDF 01-01-0001
- CYBN 11-12-2025
- Dividend Yield
- EDF 13.14%
- CYBN N/A
- EPS Growth
- EDF N/A
- CYBN N/A
- EPS
- EDF N/A
- CYBN N/A
- Revenue
- EDF N/A
- CYBN N/A
- Revenue This Year
- EDF N/A
- CYBN N/A
- Revenue Next Year
- EDF N/A
- CYBN N/A
- P/E Ratio
- EDF N/A
- CYBN N/A
- Revenue Growth
- EDF N/A
- CYBN N/A
- 52 Week Low
- EDF $3.51
- CYBN $4.81
- 52 Week High
- EDF $5.50
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- EDF N/A
- CYBN 47.09
- Support Level
- EDF N/A
- CYBN $5.93
- Resistance Level
- EDF N/A
- CYBN $6.63
- Average True Range (ATR)
- EDF 0.00
- CYBN 0.34
- MACD
- EDF 0.00
- CYBN 0.07
- Stochastic Oscillator
- EDF 0.00
- CYBN 46.71
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.